creatine has been researched along with Recrudescence in 38 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cyclosporine dose adjustments were performed based on blood cyclosporine T6 enzyme-multiplied immunologic technique, irrespective of T0 and serum creatinine (SCr), in eight steroid- or azathioprine-resistant uveitis patients." | 7.69 | Cyclosporine monitoring with levels 6 hours after the morning dose in patients with noninfectious uveitis. ( Cantarovich, M; Deschênes, J; Rocha, G, 1997) |
| "The authors examined the levels of NAA, creatine plus phosphocreatine, and choline-containing molecules in the left dorsolateral prefrontal cortex of 14 bipolar disorder patients (mean age=15." | 3.73 | Reduced NAA levels in the dorsolateral prefrontal cortex of young bipolar patients. ( Axelson, D; Birmaher, B; Brambilla, P; Keshavan, MS; Nicoletti, MA; Ramos, RT; Ryan, N; Sassi, RB; Soares, JC; Stanley, JA, 2005) |
| "Creatine monohydrate given orally led to a long-lasting improvement of muscular weakness and ataxia in a girl with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency." | 3.72 | Striking improvement of muscle strength under creatine therapy in a patient with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency. ( Hanefeld, F; Korenke, GC; Wanders, RJ, 2003) |
| "Rats in experiment 1 received 1% creatine or cyclocreatine chow from age (P) 21-65 days, underwent kainate induced status epilepticus on P35 and were compared, as adults, to kainate alone rats and to normal controls." | 3.72 | Effects of creatine and cyclocreatine supplementation on kainate induced injury in pre-pubescent rats. ( Abu Rialy, S; Farhat, F; Francis, E; Geha, G; Kurdit, RM; Lteif, L; Maraashli, W; Mikati, MA; Rahmeh, AA, 2004) |
| " We report a longitudinal study in which changes in the N-acetylaspartate to creatine resonance intensity ratio measured by brain proton magnetic resonance spectroscopy were used to follow the progression of brain pathology in 7 patients with multiple sclerosis over an 18-month period." | 3.69 | Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. ( Antel, JP; Arnold, DL; Collins, DL; Francis, GS; Matthews, PM; Riess, GT; Wolfson, C, 1994) |
| "Cyclosporine dose adjustments were performed based on blood cyclosporine T6 enzyme-multiplied immunologic technique, irrespective of T0 and serum creatinine (SCr), in eight steroid- or azathioprine-resistant uveitis patients." | 3.69 | Cyclosporine monitoring with levels 6 hours after the morning dose in patients with noninfectious uveitis. ( Cantarovich, M; Deschênes, J; Rocha, G, 1997) |
| "The incidence of Clostridium difficile infection (CDI) has risen dramatically during the last decade." | 2.79 | Risk estimation for recurrent Clostridium difficile infection based on clinical factors. ( Collins, SH; D'Agostino, RB; Gorbach, S; Kean, Y; Pencina, KM, 2014) |
| "In conclusion, both leukocytosis and renal failure are useful predictors, although timing of measurement is important." | 1.38 | Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis. ( Bauer, MP; Dale, AP; Fawley, WN; Gerding, DN; Gorbach, SL; Hensgens, MP; Kuijper, EJ; Miller, MA; Wilcox, MH, 2012) |
| " When administering cancer chemotherapy to the elderly aged 70 and older, the patient's renal function, PS and Ccr, should be studied, and a regimen and dosage should be carefully selected." | 1.38 | [Tolerable evaluation for chemotherapy with S-1 plus cisplatin in elderly patients with advanced and recurrent gastric cancer]. ( Ito, D; Iwai, M; Kimura, M; Nakao, T; Okada, K; Usami, E; Yasuda, T; Yoshimura, T, 2012) |
| "Bladder cancer is the fourth most common malignant neoplasm in men and the tenth most common in women." | 1.32 | Analytical and clinical evaluation of a new urinary tumor marker: bladder tumor fibronectin in diagnosis and follow-up of bladder cancer. ( Emerk, K; Mutlu, N; Turkeri, L, 2003) |
| "Disease recurrence is less well described." | 1.31 | Treatment of parvovirus B-19 (PV B-19) infection allows for successful kidney transplantation without disease recurrence. ( Barsoum, NR; Bunnapradist, S; Jordan, SC; Mougdil, A; Toyoda, M; Vo, A, 2002) |
| "Thirty patients who had gastric varices with gastrorenal or gastrocaval collaterals underwent balloon-occluded retrograde transvenous obliteration." | 1.29 | Balloon-occluded retrograde transvenous obliteration for gastric varices with gastrorenal or gastrocaval collaterals. ( Koito, K; Morita, K; Nagakawa, T; Namieno, T, 1996) |
| "In regard to diabetic complications, recurrence of diabetic nephropathy was common, but only two patients lost graft function solely for this reason." | 1.28 | Long-term survival following kidney transplantation in 100 type I diabetic patients. ( Fryd, DS; Goetz, FC; Kaufman, DB; Kennedy, WR; Mauer, SM; McHugh, L; Najarian, JS; Navarro, X; Ramsay, RC; Sutherland, DE, 1989) |
| "In study 3, stone recurrence, assessed prospectively, felt significantly in patients given a high fluid intake alone or associated with 50 mg/d of hydrochlorothiazide, independently of urinary calcium excretion." | 1.27 | [Predictive value of lithogenic risk in hypercalciuria: should 24-hour urine calcium be measured?]. ( Ulmann, A, 1984) |
| "The mean frequency of recurrence was 40% and the mean frequency of infection 12%." | 1.25 | Incidence, morbidity and complications of renal and ureteral calculi in a well defined geographical area. ( Almby, B; Meirik, O; Schönebeck, J, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (15.79) | 18.7374 |
| 1990's | 11 (28.95) | 18.2507 |
| 2000's | 13 (34.21) | 29.6817 |
| 2010's | 8 (21.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| D'Agostino, RB | 1 |
| Collins, SH | 1 |
| Pencina, KM | 1 |
| Kean, Y | 1 |
| Gorbach, S | 1 |
| Zahr, NM | 1 |
| Carr, RA | 1 |
| Rohlfing, T | 1 |
| Mayer, D | 1 |
| Sullivan, EV | 1 |
| Colrain, IM | 1 |
| Pfefferbaum, A | 1 |
| van Hoeve, K | 1 |
| Vandermeulen, C | 1 |
| Van Ranst, M | 1 |
| Levtchenko, E | 1 |
| van den Heuvel, L | 1 |
| Mekahli, D | 1 |
| Durazzo, TC | 2 |
| Pathak, V | 1 |
| Gazdzinski, S | 1 |
| Mon, A | 1 |
| Meyerhoff, DJ | 2 |
| Mashhoon, Y | 1 |
| Janes, AC | 1 |
| Jensen, JE | 1 |
| Prescot, AP | 1 |
| Pachas, G | 1 |
| Renshaw, PF | 1 |
| Fava, M | 1 |
| Evins, AE | 1 |
| Kaufman, MJ | 1 |
| Ende, G | 2 |
| Bauer, MP | 1 |
| Hensgens, MP | 1 |
| Miller, MA | 1 |
| Gerding, DN | 1 |
| Wilcox, MH | 1 |
| Dale, AP | 1 |
| Fawley, WN | 1 |
| Kuijper, EJ | 1 |
| Gorbach, SL | 1 |
| Kimura, M | 1 |
| Usami, E | 1 |
| Ito, D | 1 |
| Iwai, M | 1 |
| Okada, K | 1 |
| Nakao, T | 1 |
| Yoshimura, T | 1 |
| Yasuda, T | 1 |
| Barsoum, NR | 1 |
| Bunnapradist, S | 1 |
| Mougdil, A | 1 |
| Toyoda, M | 1 |
| Vo, A | 1 |
| Jordan, SC | 1 |
| Sarchielli, P | 1 |
| Presciutti, O | 1 |
| Tarducci, R | 1 |
| Gobbi, G | 1 |
| Alberti, A | 1 |
| Pelliccioli, GP | 1 |
| Chiarini, P | 1 |
| Gallai, V | 1 |
| Parry, A | 1 |
| Corkill, R | 1 |
| Blamire, AM | 1 |
| Palace, J | 1 |
| Narayanan, S | 4 |
| Arnold, D | 1 |
| Styles, P | 1 |
| Matthews, PM | 4 |
| Inglese, M | 1 |
| Li, BS | 1 |
| Rusinek, H | 1 |
| Babb, JS | 1 |
| Grossman, RI | 1 |
| Gonen, O | 1 |
| Korenke, GC | 1 |
| Wanders, RJ | 1 |
| Hanefeld, F | 1 |
| Obergriesser, T | 1 |
| Braus, DF | 1 |
| Henn, FA | 1 |
| Mutlu, N | 1 |
| Turkeri, L | 1 |
| Emerk, K | 1 |
| Ruiz-Peña, JL | 1 |
| Piñero, P | 1 |
| Sellers, G | 1 |
| Argente, J | 1 |
| Casado, A | 1 |
| Foronda, J | 1 |
| Uclés, A | 1 |
| Izquierdo, G | 1 |
| Mikati, MA | 1 |
| Kurdit, RM | 1 |
| Rahmeh, AA | 1 |
| Farhat, F | 1 |
| Abu Rialy, S | 1 |
| Lteif, L | 1 |
| Francis, E | 1 |
| Geha, G | 1 |
| Maraashli, W | 1 |
| Sassi, RB | 1 |
| Stanley, JA | 1 |
| Axelson, D | 1 |
| Brambilla, P | 1 |
| Nicoletti, MA | 1 |
| Keshavan, MS | 1 |
| Ramos, RT | 1 |
| Ryan, N | 1 |
| Birmaher, B | 1 |
| Soares, JC | 1 |
| Raedler, TJ | 1 |
| Wiedemann, K | 1 |
| Bhagwagar, Z | 1 |
| Wylezinska, M | 1 |
| Jezzard, P | 1 |
| Evans, J | 1 |
| Boorman, E | 1 |
| M Matthews, P | 1 |
| J Cowen, P | 1 |
| Ulmann, A | 1 |
| Bizzi, A | 1 |
| Movsas, B | 1 |
| Tedeschi, G | 1 |
| Phillips, CL | 1 |
| Okunieff, P | 1 |
| Alger, JR | 1 |
| Di Chiro, G | 1 |
| Arnold, DL | 4 |
| Riess, GT | 1 |
| Francis, GS | 3 |
| Collins, DL | 2 |
| Wolfson, C | 2 |
| Antel, JP | 3 |
| Yeung, CY | 1 |
| Lee, HC | 1 |
| Huang, FY | 1 |
| Ho, MY | 1 |
| Kao, HA | 1 |
| Liang, DC | 1 |
| Hsu, CH | 1 |
| Hung, HY | 1 |
| Chang, PY | 1 |
| Sheu, JC | 1 |
| Pan, JW | 1 |
| Hetherington, HP | 1 |
| Vaughan, JT | 1 |
| Mitchell, G | 1 |
| Pohost, GM | 1 |
| Whitaker, JN | 1 |
| Koito, K | 1 |
| Namieno, T | 1 |
| Nagakawa, T | 1 |
| Morita, K | 1 |
| Rocha, G | 1 |
| Deschênes, J | 1 |
| Cantarovich, M | 1 |
| Fu, L | 2 |
| Worsley, KJ | 1 |
| De Stefano, N | 3 |
| Greenhaff, P | 1 |
| Stanley, J | 1 |
| Daly, KA | 1 |
| Brown, JE | 1 |
| Lindgren, BR | 1 |
| Meland, MH | 1 |
| Le, CT | 1 |
| Giebink, GS | 1 |
| Ness, SR | 1 |
| McCarty, MF | 1 |
| Barratt, TM | 1 |
| Bercowsky, A | 1 |
| Osofsky, SG | 1 |
| Soothill, JF | 1 |
| Matas, AJ | 1 |
| Simmons, RL | 1 |
| Kjellstrand, CM | 1 |
| Najarian, JS | 2 |
| Almby, B | 1 |
| Meirik, O | 1 |
| Schönebeck, J | 1 |
| Kaufman, DB | 1 |
| Fryd, DS | 1 |
| McHugh, L | 1 |
| Mauer, SM | 1 |
| Ramsay, RC | 1 |
| Kennedy, WR | 1 |
| Navarro, X | 1 |
| Goetz, FC | 1 |
| Sutherland, DE | 1 |
| Rymsha, VF | 1 |
| Pinevich, EE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-Blind Study to Compare the Safety and Efficacy of PAR-101 to Vancomycin in Subjects With Clostridium Difficile-Associated Diarrhea (CDAD)[NCT00468728] | Phase 3 | 535 participants (Actual) | Interventional | 2006-10-04 | Completed | ||
| A Multi-National, Multi-Center, Double-Blind, Randomized, Parallel Group Study to Compare the Safety and Efficacy of 200 mg PAR-101 Taken q12h With 125 mg Vancomycin Taken q6h for Ten Days in Subjects With Clostridium Difficile-Associated Diarrhea[NCT00314951] | Phase 3 | 629 participants (Actual) | Interventional | 2006-05-02 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of subjects with 3 or fewer unformed stools for 2 consecutive days and maintained through the end of therapy, and the subject no longer needed specific anti-Clostridium antibacterial treatment after completion of the course of study medication. (NCT00468728)
Timeframe: Study day 10 (+/- 2 days)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Vancomycin | 86.7 |
| PAR-101/OPT-80 | 87.7 |
Achieving a cure response at end of treatment and not having a recurrence at any time up to the post-study visit. (NCT00468728)
Timeframe: End of Study
| Intervention | Percentage of Participants (Number) |
|---|---|
| Vancomycin | 63.3 |
| PAR-101/OPT-80 | 76.7 |
Percentage of subjects with the re-establishment of diarrhea to an extent(based on frequency of passed unformed stools) that was greater than that noted on the last day of study medication, and the demonstration of either toxin A or B or both of C. difficile, and retreatment with CDI anti-infective therapy was needed. (NCT00468728)
Timeframe: Study days 11-40
| Intervention | Percentage of Participants (Number) |
|---|---|
| Vancomycin | 27.0 |
| PAR-101/OPT-80 | 12.6 |
Percentage of participants with 3 or fewer unformed stools for 2 consecutive days and maintained through the end of therapy, and the subject no longer needed specific anti-Clostridium antibacterial treatment after completion of the course of study medication. (NCT00314951)
Timeframe: Study day 10 (+/- 2 days)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Vancomycin | 85.7 |
| Fidaxomicin | 88.2 |
Percentage of participants who were cured (3 or fewer unformed stools for 2 days through the end of therapy, and no C. difficile therapy after study drug completion) and didn't have recurrence (re-establishment of diarrhea that was greater than on the last day of study drug, positive C. difficile toxin and retreatment with C. difficile therapy) up to Day 40. (NCT00314951)
Timeframe: End of Study (Day 40)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Vancomycin | 64.2 |
| Fidaxomicin | 74.4 |
Percentage of participants with the re-establishment of diarrhea to an extent(based on frequency of passed unformed stools) that was greater than that noted on the last day of study medication, and the demonstration of either toxin A or B or both of C. difficile, and retreatment with CDI anti-infective therapy was needed. (NCT00314951)
Timeframe: Study days 11-40
| Intervention | Percentage of Participants (Number) |
|---|---|
| Vancomycin | 25.1 |
| Fidaxomicin | 15.7 |
3 reviews available for creatine and Recrudescence
| Article | Year |
|---|---|
Chronic alcohol consumption, abstinence and relapse: brain proton magnetic resonance spectroscopy studies in animals and humans.
Topics: Alcohol Drinking; Alcohol-Related Disorders; Animals; Asparagine; Brain; Chronic Disease; Creatine; | 2013 |
Lithium-induced nephropathies.
Topics: Adult; Antimanic Agents; Bipolar Disorder; Creatine; Diabetes Insipidus, Nephrogenic; Dose-Response | 2007 |
Pancreatitis in children--experience with 43 cases.
Topics: Abdomen, Acute; Adolescent; Amylases; Child; Child, Preschool; Creatine; Diagnostic Imaging; Female; | 1996 |
4 trials available for creatine and Recrudescence
| Article | Year |
|---|---|
Risk estimation for recurrent Clostridium difficile infection based on clinical factors.
Topics: Adult; Age Factors; Aged; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostrid | 2014 |
Risk estimation for recurrent Clostridium difficile infection based on clinical factors.
Topics: Adult; Age Factors; Aged; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostrid | 2014 |
Risk estimation for recurrent Clostridium difficile infection based on clinical factors.
Topics: Adult; Age Factors; Aged; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostrid | 2014 |
Risk estimation for recurrent Clostridium difficile infection based on clinical factors.
Topics: Adult; Age Factors; Aged; Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostrid | 2014 |
Beta-Interferon treatment does not always slow the progression of axonal injury in multiple sclerosis.
Topics: Adult; Aspartic Acid; Axons; Body Water; Brain Chemistry; Cohort Studies; Creatine; Disease Progress | 2003 |
Diffusely elevated cerebral choline and creatine in relapsing-remitting multiple sclerosis.
Topics: Adult; Aspartic Acid; Brain; Choline; Corpus Callosum; Creatine; Diffusion; Female; Humans; Magnetic | 2003 |
Magnetic resonance spectroscopy of normal appearing white matter in early relapsing-remitting multiple sclerosis: correlations between disability and spectroscopy.
Topics: Adolescent; Adult; Aged; Aspartic Acid; Axons; Biomarkers; Brain; Creatine; Cross-Sectional Studies; | 2004 |
31 other studies available for creatine and Recrudescence
| Article | Year |
|---|---|
Brain metabolite levels in recently sober individuals with alcohol use disorder: Relation to drinking variables and relapse.
Topics: Adult; Alcohol Abstinence; Alcohol Drinking; Alcoholism; Aspartic Acid; Brain; Choline; Chronic Dise | 2016 |
Occurrence of atypical HUS associated with influenza B.
Topics: Adolescent; Atypical Hemolytic Uremic Syndrome; Biomarkers; Child; Creatine; Humans; Influenza B vir | 2017 |
Metabolite levels in the brain reward pathway discriminate those who remain abstinent from those who resume hazardous alcohol consumption after treatment for alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Aspartic Acid; Brain; Creatine; Female; Follow-Up Studies; Huma | 2010 |
Anterior cingulate proton spectroscopy glutamate levels differ as a function of smoking cessation outcome.
Topics: Administration, Cutaneous; Creatine; Female; Glutamic Acid; Gyrus Cinguli; Humans; Magnetic Resonanc | 2011 |
Renal failure and leukocytosis are predictors of a complicated course of Clostridium difficile infection if measured on day of diagnosis.
Topics: Aminoglycosides; Anti-Bacterial Agents; Clostridioides difficile; Clostridium Infections; Confidence | 2012 |
[Tolerable evaluation for chemotherapy with S-1 plus cisplatin in elderly patients with advanced and recurrent gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Creatine; | 2012 |
Treatment of parvovirus B-19 (PV B-19) infection allows for successful kidney transplantation without disease recurrence.
Topics: Acute Kidney Injury; Antiviral Agents; Creatine; Female; Ganciclovir; Graft Rejection; Hemoglobins; | 2002 |
Localized (1)H magnetic resonance spectroscopy in mainly cortical gray matter of patients with multiple sclerosis.
Topics: Adult; Aspartic Acid; Atrophy; Creatine; Disease Progression; Female; Humans; Magnetic Resonance Spe | 2002 |
Striking improvement of muscle strength under creatine therapy in a patient with long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Child; Creatine; Female; Humans; Lipid Metabolism, Inborn Errors; | 2003 |
Long-term follow-up of magnetic resonance-detectable choline signal changes in the hippocampus of patients treated with electroconvulsive therapy.
Topics: Aspartic Acid; Choline; Cognition Disorders; Creatine; Depressive Disorder, Major; Electroconvulsive | 2003 |
Analytical and clinical evaluation of a new urinary tumor marker: bladder tumor fibronectin in diagnosis and follow-up of bladder cancer.
Topics: Biomarkers, Tumor; Creatine; Data Interpretation, Statistical; Disease Progression; Female; Fibronec | 2003 |
Effects of creatine and cyclocreatine supplementation on kainate induced injury in pre-pubescent rats.
Topics: Acute Disease; Aggression; Animals; Anticonvulsants; Creatine; Creatinine; Dietary Supplements; Emot | 2004 |
Reduced NAA levels in the dorsolateral prefrontal cortex of young bipolar patients.
Topics: Adolescent; Adult; Age Factors; Aspartic Acid; Bipolar Disorder; Child; Choline; Creatine; Female; H | 2005 |
Low GABA concentrations in occipital cortex and anterior cingulate cortex in medication-free, recovered depressed patients.
Topics: Adult; Case-Control Studies; Creatine; Depressive Disorder, Major; Down-Regulation; Feasibility Stud | 2008 |
[Predictive value of lithogenic risk in hypercalciuria: should 24-hour urine calcium be measured?].
Topics: Calcium; Creatine; Follow-Up Studies; Humans; Hydrochlorothiazide; Hyperparathyroidism; Kidney Calcu | 1984 |
Response of non-Hodgkin lymphoma to radiation therapy: early and long-term assessment with H-1 MR spectroscopic imaging.
Topics: Aspartic Acid; Brain Neoplasms; Choline; Creatine; Female; Follow-Up Studies; Humans; Lipid Metaboli | 1995 |
Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis.
Topics: Aspartic Acid; Axons; Brain; Creatine; Follow-Up Studies; Humans; Longitudinal Studies; Magnetic Res | 1994 |
Evaluation of multiple sclerosis by 1H spectroscopic imaging at 4.1 T.
Topics: Adult; Aspartic Acid; Astrocytes; Axons; Brain; Cell Membrane; Cerebral Ventricles; Choline; Creatin | 1996 |
Balloon-occluded retrograde transvenous obliteration for gastric varices with gastrorenal or gastrocaval collaterals.
Topics: Ammonia; Bilirubin; Blood Urea Nitrogen; Catheterization; Collateral Circulation; Contrast Media; Cr | 1996 |
Cyclosporine monitoring with levels 6 hours after the morning dose in patients with noninfectious uveitis.
Topics: Adult; Aged; Creatine; Cyclosporine; Drug Monitoring; Female; Follow-Up Studies; Glomerular Filtrati | 1997 |
Statistics for investigation of multimodal MR imaging data and an application to multiple sclerosis patients.
Topics: Aspartic Acid; Brain; Creatine; Disease Progression; Humans; Image Interpretation, Computer-Assisted | 1996 |
Axonal dysfunction and disability in a relapse of multiple sclerosis: longitudinal study of a patient.
Topics: Adult; Aspartic Acid; Axons; Brain; Creatine; Disabled Persons; Humans; Longitudinal Studies; Magnet | 1997 |
Renal dysfunction accompanying oral creatine supplements.
Topics: Administration, Oral; Creatine; Dietary Supplements; Humans; Nephrotic Syndrome; Recurrence; Renal I | 1998 |
Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study.
Topics: Aspartic Acid; Axons; Brain; Creatine; Disability Evaluation; Disease Progression; Humans; Longitudi | 1998 |
Epidemiology of otitis media onset by six months of age.
Topics: Acute Disease; Adult; Age Distribution; Age of Onset; Anti-Bacterial Agents; Chronic Disease; Cotini | 1999 |
Does supplemental creatine prevent herpes recurrences?
Topics: Animals; Creatine; Herpes Genitalis; Herpesvirus 1, Human; Herpesvirus 2, Human; Humans; Mice; Recur | 2001 |
Cyclophosphamide treatment in steroid-sensitive nephrotic syndrome of childhood.
Topics: Administration, Oral; Adolescent; Albuminuria; Body Height; Body Weight; Child; Child, Preschool; Co | 1975 |
Pseudorejection: factors mimicking rejection in renal allograft recipients.
Topics: Adolescent; Adult; Bacterial Infections; Child; Child, Preschool; Creatine; Cysts; Female; Graft Rej | 1977 |
Incidence, morbidity and complications of renal and ureteral calculi in a well defined geographical area.
Topics: Adolescent; Adult; Age Factors; Aged; Calcium; Child; Creatine; Female; Humans; Kidney Calculi; Male | 1975 |
Long-term survival following kidney transplantation in 100 type I diabetic patients.
Topics: Age Factors; Cadaver; Creatine; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Diabetic Neuropat | 1989 |
[Changes of certain biochemical indicators of blood during the treatment of patients with tuberculosis of a single kidney].
Topics: Adult; Antitubercular Agents; Blood Proteins; Creatine; Female; Humans; Male; Middle Aged; Nephrecto | 1974 |